Transcranial magnetic stimulation (TMS) is a promising intervention for adolescents with treatment-resistant depression (TRD). However, the durability of TMS-related improvement in adolescents is unclear. This 6-month study followed adolescents with TRD who had responded to TMS and provided TMS retreatment for adolescents with a partial relapse.
Methods:
The study enrolled adolescents (12–21 years) with TRD who had at least a partial response to sham or active TMS in a randomized controlled trial. Partial response was defined as ≥25% reduction of Hamilton Depression Rating Scale-24 (HAMD24). Participants with a partial relapse (≥1 point increase in Clinical Global Impression–Severity) received retreatment with daily 10 Hz TMS sessions until depressive symptom severity returned to the baseline score or after 30 TMS treatments.
Results:
There were 84 eligible participants, 66 were enrolled, and 41 completed the 6-month study. Twenty-eight participants (42%) were retreated with TMS. TMS retreatment courses had a mean of 22 sessions. At the 6-month follow-up, the complete sample exhibited reduced depressive symptoms (mean HAMD24 of 5.24) compared with baseline at entry into follow-up (mean HAMD24 of 8.21). Baseline depressive symptom severity was positively correlated with the risk of partial relapse, while the number of previous TMS interventions showed no correlation with the risk of partial relapse. TMS was well tolerated.
Conclusions:
This is the largest, long-term follow-up study with TMS retreatment for adolescents with TRD. These findings demonstrate the feasibility and clinical effects of a TMS retreatment protocol for adolescents with TRD, following a standard course of acute TMS.
Get full access to this article
View all access options for this article.
References
1.
AvenevoliS, SwendsenJ, HeJP, et al.Major depression in the national comorbidity survey-adolescent supplement: Prevalence, correlates, and treatment. J Am Acad Child Adolesc Psychiatry, 2015; 54(1):37–44.e32; doi: 10.1016/j.jaac.2014.10.010
2.
BeamW, BorckardtJJ, ReevesST, et al.An efficient and accurate new method for locating the F3 position for prefrontal TMS applications. Brain Stimul, 2009; 2(1):50–54; doi: 10.1016/j.brs.2008.09.006
3.
BernsteinIH, RushAJ, TrivediMH, et al.Psychometric properties of the Quick Inventory of Depressive Symptomatology in adolescents. Int J Methods Psychiatr Res, 2010; 19(4):185–194; doi: 10.1002/mpr.321
4.
BrentD, EmslieG, ClarkeG, et al.Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA Randomized Controlled Trial. JAMA, 2008; 299(8):901–913; doi: 10.1001/jama.299.8.901
5.
BurkeMJ, RomanellaSM, MencarelliL, et al.Placebo effects and neuromodulation for depression: A meta-analysis and evaluation of shared mechanisms. Mol Psychiatry, 2022; 27(3):1658–1666; doi: 10.1038/s41380-021-01397-3
6.
CarpenterLL, AaronsonST, HuttonTM, et al.The impact of treatment gaps on effectiveness of transcranial magnetic stimulation in MD. In: Annual Meeting of the Clinical TMS Society London, 2024.
7.
ColeEJ, PhillipsAL, BentzleyBS, et al.Stanford Neuromodulation Therapy (SNT): A double-blind randomized controlled trial. Am J Psychiatry, 2022; 179(2):132–141; doi: 10.1176/appi.ajp.2021.20101429
8.
CroarkinPE, ElmaadawiAZ, AaronsonST, et al.Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: A double-blind, randomized, sham-controlled trial. Neuropsychopharmacology, 2021; 46(2):462–469; doi: 10.1038/s41386-020-00829-y
CroarkinPE, RotenbergA. Pediatric neuromodulation comes of age. J Child Adolesc Psychopharmacol, 2016; 26(7):578–581; doi: 10.1089/cap.2016.0087
11.
DengZD, RobinsPL, DannhauerM, et al.Optimizing TMS coil placement approaches for targeting the dorsolateral prefrontal cortex in depressed adolescents: An electric field modeling study. Biomedicines, 2023; 11(8); doi: 10.3390/biomedicines11082320
12.
DhamiP, MorenoS, CroarkinPE, et al.Baseline markers of cortical excitation and inhibition predict response to theta burst stimulation treatment for youth depression. Sci Rep, 2023; 13(1):19115; doi: 10.1038/s41598-023-45107-1
13.
DwyerJB, StringarisA, BrentDA, et al.Annual research review: Defining and treating pediatric treatment-resistant depression. J Child Psychol Psychiatry, 2020; 61(3):312–332; doi: 10.1111/jcpp.13202
14.
GeolyAD, KratterIH, ToosiP, et al.Sustained efficacy of Stanford Neuromodulation Therapy (SNT) in open-label repeated treatment. Am J Psychiatry, 2024; 181(1):71–73; doi: 10.1176/appi.ajp.20230113
15.
GuyW. ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs: Rockville, MD; 1976.
16.
HamiltonM. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol, 1967; 6(4):278–296; doi: 10.1111/j.2044-8260.1967.tb00530.x
17.
HathawayEE, WalkupJT, StrawnJR. Antidepressant treatment duration in pediatric depressive and anxiety disorders: How long is long enough? Curr Probl Pediatr Adolesc Health Care, 2018; 48(2):31–39; doi: 10.1016/j.cppeds.2017.12.002
18.
HettD, RogersJ, HumpstonC, et al.Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression in adolescence: A systematic review. J Affect Disord, 2021; 278:460–469; doi: 10.1016/j.jad.2020.09.058
19.
HuttonTM, AaronsonST, CarpenterLL, et al.Dosing transcranial magnetic stimulation in major depressive disorder: Relations between number of treatment sessions and effectiveness in a large patient registry. Brain Stimul, 2023; 16(5):1510–1521; doi: 10.1016/j.brs.2023.10.001
20.
JanicakPG, NahasZ, LisanbySH, et al.Durability of clinical benefit with Transcranial Magnetic Stimulation (TMS) in the treatment of pharmacoresistant major depression: Assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul, 2010; 3(4):187–199; doi: 10.1016/j.brs.2010.07.003
21.
KennardBD, EmslieGJ, MayesTL, et al.Sequential treatment with fluoxetine and relapse–prevention CBT to improve outcomes in pediatric depression. Am J Psychiatry, 2014; 171(10):1083–1090; doi: 10.1176/appi.ajp.2014.13111460
22.
LamC, HanL, McIntyreRS, et al.Comparative efficacy of omega-3 fatty acid with other interventions for depression in children and adolescents: A systematic review and network meta-analysis. J Child Adolesc Psychopharmacol, 2024; 34(7):282–291; doi: 10.1089/cap.2024.0017
23.
MayerG, AviramS, WalterG, et al.Long-term follow-up of adolescents with resistant depression treated with repetitive transcranial magnetic stimulation. J Ect, 2012; 28(2):84–86; doi: 10.1097/YCT.0b013e318238f01a
24.
MiljevicA, BaileyNW, HerringSE, et al.Potential predictors of depressive relapse following repetitive Transcranial Magnetic Stimulation: A systematic review. J Affect Disord, 2019; 256:317–323; doi: 10.1016/j.jad.2019.06.006
25.
MontgomerySA, AsbergM. A new depression scale designed to be sensitive to change. Br J Psychiatry, 1979; 134:382–389; doi: 10.1192/bjp.134.4.382
26.
PoznanskiEO, GrossmanJA, BuchsbaumY, et al.Preliminary studies of the reliability and validity of the children’s depression rating scale. J Am Acad Child Psychiatry, 1984; 23(2):191–197; doi: 10.1097/00004583-198403000-00011
27.
QiuH, LiangK, LuL, et al.Efficacy and safety of repetitive transcranial magnetic stimulation in children and adolescents with depression: A systematic review and preliminary meta-analysis. J Affect Disord, 2023; 320:305–312; doi: 10.1016/j.jad.2022.09.060
28.
RadeckiDT, RobiesonWZ, GopalkrishnanM, et al.Safety and efficacy of levomilnacipran extended release in pediatric patients aged 7-17 years with major depressive disorder: Results of two phase 3, randomized, double-blind studies. J Child Adolesc Psychopharmacol, 2024; 34(5):241–250; doi: 10.1089/cap.2023.0080
29.
SackeimHA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry, 2001; 62(Suppl 16):10–17.
30.
SackeimHA, AaronsonST, CarpenterLL, et al.When to hold and when to fold: Early prediction of nonresponse to transcranial magnetic stimulation in major depressive disorder. Brain Stimul, 2024; 17(2):272–282; doi: 10.1016/j.brs.2024.02.019
31.
SaitoT, TakahashiH, TsujiiN, et al.Efficacy of preventing relapse evaluated by a multicenter randomized double-blind placebo-controlled withdrawal study of escitalopram in japanese adolescents with major depressive disorder. J Child Adolesc Psychopharmacol, 2023; 33(10):418–427; doi: 10.1089/cap.2023.0048
32.
SiddiqiSH, KhosravaniS, RolstonJD, et al.The future of brain circuit-targeted therapeutics. Neuropsychopharmacology, 2024; 49(1):179–188; doi: 10.1038/s41386-023-01670-9
33.
SigristC, VöckelJ, MacMasterFP, et al.Transcranial magnetic stimulation in the treatment of adolescent depression: A systematic review and meta-analysis of aggregated and individual-patient data from uncontrolled studies. Eur Child Adolesc Psychiatry, 2022; 31(10):1501–1525; doi: 10.1007/s00787-022-02021-7
34.
StrawnJR, AaronsonST, ElmaadawiAZ, et al.Treatment-resistant depression in adolescents: Clinical features and measurement of treatment resistance. J Child Adolesc Psychopharmacol, 2020; 30(4):261–266; doi: 10.1089/cap.2020.0008
35.
SunCH, MaiJX, ShiZM, et al.Adjunctive repetitive transcranial magnetic stimulation for adolescents with first-episode major depressive disorder: A meta-analysis. Front Psychiatry, 2023; 14:1200738; doi: 10.3389/fpsyt.2023.1200738
36.
WallCA, CroarkinPE, SimLA, et al.Adjunctive use of repetitive transcranial magnetic stimulation in depressed adolescents: A prospective, open pilot study. J Clin Psychiatry, 2011; 72(9):1263–1269; doi: 10.4088/JCP.11m07003
37.
WilsonS, CroarkinPE, AaronsonST, et al.Systematic review of preservation TMS that includes continuation, maintenance, relapse-prevention, and rescue TMS. J Affect Disord, 2022; 296:79–88; doi: 10.1016/j.jad.2021.09.040
38.
ZhaoY, HeZ, LuoW, et al.Effect of intermittent theta burst stimulation on suicidal ideation and depressive symptoms in adolescent depression with suicide attempt: A randomized sham-controlled study. J Affect Disord, 2023; 325:618–626; doi: 10.1016/j.jad.2023.01.061
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
